Publications
Spotlight Publication
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
European Society for Medical Oncology (ESMO) GI
Jun 26
- Jun 29, 2024
Neoadjuvant botensilimab (BOT) plus balstilimab (BAL) in resectable mismatch repair proficient and deficient colorectal cancer
Kasi, et. al.
Filter by
QS-21 STIMULON™ Adjuvant
The Journal of Infectious Diseases
Nov 1, 2009
Synthetic Malaria Peptide Vaccine Elicits High Levels of Antibodies in Vaccinees of Defined HLA Genotypes.
Nardin, et al.
QS-21 STIMULON™ Adjuvant
Vaccine
Jul 16, 2001
Three Double-Blind, Randomized Trials Evaluating the Safety and Tolerance of Different Formulations of the Saponin Adjuvant QS-21.
Waite, et al.
QS-21 STIMULON™ Adjuvant
Vaccine
Feb 28, 2001
QS-21 Promotes an Adjuvant Effect Allowing for Reduced Antigen Dose During HIV-1 Envelope Subunit Immunization in Human.
Evans, et al.
QS-21 STIMULON™ Adjuvant
The Journal of Immunology
Feb 15, 2001
Oral QS-21 Requires Early IL-4 Help for Induction of Mucosal and Systemic Immunity.
Boyaka, et al.
QS-21 STIMULON™ Adjuvant
Clinical Cancer Research
May 1, 2002
T-cell Responses Against Tyrosinase 368-376(370D) Peptide in HLA*A0201+ Melanoma Patients: Randomized Trial Comparing Incomplete Freund’s Adjuvant, Granulocyte Macrophage Colony-Stimulating Factor, and QS-21 as Immunological Adjuvants.
Schaed, et al.
QS-21 STIMULON™ Adjuvant
The Journal of Immunology
Jul 15, 2005
Induction of Humoral and CD8+ T Cell Responses are Required for Protection Against Lethal Ebola Virus Infection.
Warfiled, et. al.
QS-21 STIMULON™ Adjuvant
Vaccine
Mar 4, 2008
Vaccine Adjuvant Systems Containing Monophosphoryl Lipid A and QS21 Induce Strong and Persistent Humoral and T Cell Responses Against Hepatitis B Surface Antigen in Healthy Adult Volunteers.
Vandepapelière, et al.
QS-21 STIMULON™ Adjuvant
Expert Opinion on Biological Therapy
Jun 12, 2008
Cancer Immunotherapy Targeting Tumour-Specific Antigens: Towards a New Therapy for Minimal Residual Disease.
Brichard, et al.
QS-21 STIMULON™ Adjuvant
New England Journal of Medicine
Dec 11, 2008
Efficacy of RTS,S/AS01E Vaccine Against Malaria in Children 5 to 17 Months of Age.
Bejon, et al.
QS-21 STIMULON™ Adjuvant
New England Journal of Medicine
Dec 11, 2008
Safety and Immunogenicity of RTS,S/AS02D Malaria Vaccine in Infants.
Abdulla, et al.
QS-21 STIMULON™ Adjuvant
Kidney International
Feb 1, 2010
Rapid, Enhanced, and Persistent Protection of Patients with Renal Insufficiency by AS02(V)-Adjuvanted Hepatitis B Vaccine.
Surquin, et al.
QS-21 STIMULON™ Adjuvant
Vaccine
Nov 3, 2011
A Heat Shock Protein Based Polyvalent Vaccine Targeting HSV-2: CD4(+) and CD8(+) Cellular Immunity and Protective Efficacy.
Mo, et al.